"Interferon Type I" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
Interferon secreted by leukocytes, fibroblasts, or lymphoblasts in response to viruses or interferon inducers other than mitogens, antigens, or allo-antigens. They include alpha- and beta-interferons (INTERFERON-ALPHA and INTERFERON-BETA).
| Descriptor ID |
D007370
|
| MeSH Number(s) |
D12.644.276.374.440.890 D12.776.467.374.440.890 D23.529.374.440.890
|
| Concept/Terms |
Interferon Type I- Interferon Type I
- Type I Interferons
- Interferons, Type I
- Interferons Type I
- Type I Interferon
- Interferon, Type I
|
Below are MeSH descriptors whose meaning is more general than "Interferon Type I".
Below are MeSH descriptors whose meaning is more specific than "Interferon Type I".
This graph shows the total number of publications written about "Interferon Type I" by people in this website by year, and whether "Interferon Type I" was a major or minor topic of these publications.
To see the data from this visualization as text,
click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 1998 | 1 | 2 | 3 |
| 2000 | 0 | 1 | 1 |
| 2002 | 1 | 0 | 1 |
| 2004 | 0 | 2 | 2 |
| 2005 | 1 | 0 | 1 |
| 2006 | 2 | 1 | 3 |
| 2007 | 1 | 0 | 1 |
| 2008 | 0 | 1 | 1 |
| 2009 | 4 | 0 | 4 |
| 2010 | 3 | 2 | 5 |
| 2011 | 5 | 2 | 7 |
| 2012 | 3 | 2 | 5 |
| 2013 | 2 | 0 | 2 |
| 2014 | 2 | 2 | 4 |
| 2015 | 2 | 4 | 6 |
| 2016 | 4 | 3 | 7 |
| 2017 | 2 | 3 | 5 |
| 2018 | 0 | 1 | 1 |
| 2019 | 1 | 1 | 2 |
| 2020 | 1 | 2 | 3 |
| 2021 | 2 | 4 | 6 |
| 2022 | 3 | 1 | 4 |
| 2023 | 2 | 0 | 2 |
| 2024 | 3 | 1 | 4 |
| 2025 | 1 | 3 | 4 |
| 2026 | 4 | 0 | 4 |
To return to the timeline,
click here.
Below are the most recent publications written about "Interferon Type I" by people in Profiles.
-
Low-Strength Type I Interferon Signaling Promotes CAR T-cell Treatment Efficacy. Cancer Immunol Res. 2026 Aug 04; 14(8):1292-1306.
-
IFN signaling at the nexus of the radiotherapy response in malignant peripheral nerve sheath tumors. J Clin Invest. 2026 Mar 02; 136(5).
-
Chromatin-mediated anticipatory control of type I interferon production in plasmacytoid dendritic cells. Immunity. 2026 Feb 10; 59(2):270-287.e11.
-
Interferon-sensitized hematopoietic progenitors dynamically alter organismal immunity. J Immunol. 2026 01 21; 215(1).
-
Tonic type I interferon signaling optimizes the antiviral function of plasmacytoid dendritic cells. Nat Immunol. 2025 Nov; 26(11):1946-1961.
-
PARP7 inhibition stabilizes STAT1/STAT2 and relieves experimental autoimmune encephalomyelitis in mice. Cell Rep. 2025 Aug 26; 44(8):116130.
-
Immunoglobulin A controls intestinal virus colonization to preserve immune homeostasis. Cell Host Microbe. 2025 Apr 09; 33(4):498-511.e10.
-
ß-Glucan reprograms neutrophils to promote disease tolerance against influenza A virus. Nat Immunol. 2025 Feb; 26(2):174-187.
-
YTHDF1 loss in dendritic cells potentiates radiation-induced antitumor immunity via STING-dependent type I IFN production. J Clin Invest. 2024 12 02; 134(23).
-
Cancer cells restrict immunogenicity of retrotransposon expression via distinct mechanisms. Immunity. 2024 12 10; 57(12):2879-2894.e11.